XML 66 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Revenues:      
Collaborative research and development $ 2,080 $ 3,612 $ 22,570
Royalty income 1,446 1,353 483
Total revenues 3,526 [1],[2] 4,965 [3] 23,053
Operating expenses:      
Research and development 7,039 6,864 6,994
General and administrative 6,868 8,104 6,968
Impairment of intangible assets 14,830    
Total operating expenses 28,737 14,968 13,962
Operating (loss) income (25,211) [1],[2] (10,003) [3] 9,091
Other income (expense):      
Change in fair value of derivatives 170 1,140 (339)
Interest income, net 38 30 27
Other expense, net (1) (13) (3)
Total other income (expense) 207 1,157 (315)
(Loss) income before income taxes (25,004) (8,846) 8,776
Income tax benefit (expense) 169 218 (23)
Net (loss) income $ (24,835) [1],[2] $ (8,628) [3] $ 8,753
Net (loss) income per share:      
Basic $ (1.19) $ (0.44) $ 0.48
Diluted $ (1.19) $ (0.44) $ 0.46
Weighted average common shares outstanding:      
Basic 20,791 19,489 18,405
Diluted 20,791 19,489 18,895
[1] Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).
[2] Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)
[3] Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).